Navigation Links
Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
Date:1/31/2011

MADISON, N.J., Jan. 31, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics.

"Through this transaction, we are taking advantage of a unique opportunity to enhance shareholder value and demonstrating confidence in the long term outlook for our business," said Surya N. Mohapatra, Chairman and CEO of Quest Diagnostics. "We continue to maintain the financial flexibility to pursue acquisitions, which remains a key element of our growth strategy."

Quest Diagnostics will repurchase the shares using a combination of cash on hand and borrowing through available credit facilities. The repurchase will be applied against the company's current $1 billion share repurchase authorization.

As a result of this transaction, the company is raising its 2011 guidance for diluted earnings per share before special items to be between $4.25 to $4.45. Previous guidance was $4.10 to $4.30.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 The American Association for Homecare (AAHomecare), along ... , announced today the filing of a lawsuit ... , asking that the scheduled July 1 expansion of ... (DME) be stopped because of serious licensing irregularities. ... (HHS) Secretary Kathleen Sebelius as the defendant. ...
(Date:6/19/2013)... 19, 2013 Amgen is pleased to announce the ... , Canada and Puerto ... Amgen Award for Science Teaching Excellence (AASTE). Now in its ... through 12th grade level who have an outstanding ability to ... With a long-standing commitment to science education, Amgen established the ...
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in ... lymphocytic lymphoma (SLL). Ibrutinib was shown to be safe ... even in patients who were at high-risk due to ...
Breaking Medicine Technology:AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6
... Texas and KOLN, Germany, June 8, 2011 Luminex ... der Stadt Koln, Institute of Pathology and Institute for ... Pathogen Panel (GPP) is being used successfully as a ... suspected of having an E. coli infection.  This includes ...
... Company (NYSE: LLY ) today announced that ... California ruled in Lilly,s favor, vacating a temporary restraining ... a preliminary injunction that sought to impose restrictions on ... recently filed litigation involving the two companies, diabetes collaboration ...
Cached Medicine Technology:Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 2Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 3Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 4U.S. District Court Rules in Favor of Lilly in Amylin Litigation 2
(Date:6/19/2013)... PrettySkin4Less announces it is stocking up with ... top skin care manufacturer EMINENCE to meet customer demands. ... and active organic ingredients to promote actual change rather ... products offer. For this reason it’s not hard to ... like products that do what they say they will ...
(Date:6/19/2013)... 2013 Strict rules for ... Orriant is launching a new tool to help ... with regulations. New HHS regulations will soon ... if their employer offers outcome-based, health-contingent, compliant wellness ... with these standards for nearly a decade. Orriant ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... , TUESDAY, Dec. 14 (HealthDay News) -- ... genetic mutations associated with adrenal gland tumors by identifying ... affect the adrenal gland, which is located above the ... can also be cancerous -- cause the adrenal gland ...
... R.I. [Brown University] Brown University sociologists have ... about risky sexual behavior among Ethiopian teenagers and ... Simple, portable, low-cost, and low-tech, the group,s new ... and confidentially during face-to-face interviews. Professors of sociology ...
... Dec. 14 (HealthDay News) -- Two reports from the U.S. ... is hitting young and older Americans across the economic,spectrum. ... and Prevention, released the reports on Tuesday. Looking at ... data from 1988 to 1994 and from 2005 to 2008, ...
... Dec. 14, 2010 Cancer Research Institute, Inc. (CRI), ... the science of tumor immunology and foster the discovery ... the Cancer Vaccine Acceleration Fund (CVAF), a new model ... with the Ludwig Institute for Cancer Research Ltd (LICR) ...
... French . , MONTREAL, December 14, 2010 The ... learn to recognize the sound of their parents, voice and the ... parents and newborns admitted to the intensive care unit can be ... , Jan Lariviere, a nurse in the neonatal clinic and the ...
... Gardner HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... the most from health-care reform, a new report shows. ... the elimination of restrictions on people with preexisting conditions, while ... subsidized coverage through health insurance exchanges -- are slated for ...
Cached Medicine News:Health News:New survey device gets better information on teenage sexual behavior 2Health News:New survey device gets better information on teenage sexual behavior 3Health News:Obesity Rising Across All Income Levels: CDC 2Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 2Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 3Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 4Health News:Once upon a time in the Intensive Care Unit ... 2Health News:Report Finds Baby Boomers to Gain Most From Health Care Reform 2Health News:Report Finds Baby Boomers to Gain Most From Health Care Reform 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: